Rare Partners is a non profit company devoted to the development of new therapies and diagnostics in the field of rare diseases.
The clinical trial Sirthalaclin for the treatment of transfusion-dependent beta-thalassemia patients has started patient enrolment.
FDA grants Orphan Drug Designation for the use of teicoplanin in Staphylococcus aureus infections in cf patients.
Wellcome Trust supports the development of sirolimus in beta - thalassemia, a collaborative project between Rare Partners and Ferrara University
